HemoBioTech's CEO, Arthur Bollon, Ph.D., To Present Strategic Vision At The SCIA National Small Cap Syndicate Capital Conference
DALLAS, Aug 07, 2008 (BUSINESS WIRE) -- HemoBioTech, Inc. (OTCBB: HMBT) (www.hemobiotech.com) announced today that Arthur Bollon, Ph.D., Chairman and Chief Executive Officer of HemoBioTech, will be presenting at the 2008 Southern California Investment Association (SCIA) Capital Conference in Orange County, CA on Saturday, August 9, 2008 at the Orange County Airport Hilton.
Dr. Bollon will make a presentation of the company's progressive HemoTech red blood cell substitute technology as well as the Orthogonal purification technology for clearance of viruses and prions during the production of animal and human derived products for use in humans.
"We are excited to have the opportunity to present our strategic vision to the members of the Southern California Investment Association," said Dr. Arthur P. Bollon, Chairman & CEO of HemoBioTech, Inc. "This function gathers a national alliance of influential firms plus brokers, high net worth investors, institutions and funds anticipating new opportunities."
The SCIA Capital Conference Presentation is limited to SCIA members. An agenda for the event, registration, attendance details, and information about SCIA are available at the SCIA Web site: http://www.sciaonline.org.
About HemoBioTech, Inc.
HemoBioTech is engaged in the commercial development of HemoTech, a novel human blood substitute technology developed by Texas Tech University Health Sciences Center scientists, Drs. Mario Feola and Jan Simoni, and exclusively licensed from Texas Tech University System. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, Adenosine and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The Company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. HemoTech is being subjected to further studies and testing to confirm and expand on these studies. At a recent meeting in April, 2008 by the U.S. Food and Drug Administration (FDA) for blood substitutes, the FDA indicated the need for a new generation of hemoglobin based blood substitutes for development and the Adenosine-GSH approach of HemoBioTech was cited. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions.
HemoBioTech received an exclusive worldwide license from the Texas Tech University System for a new technology that addresses the safety of animal-derived products for human use in pharmaceutical, cosmetic and other industries. This new technology acts to prevent the spread of transmissible spongiform encephalopathies (TSE), also know as prions or mad cow disease, as well as viruses. The FDA strictly regulates medicinal products and cosmetics that contain ingredients from animals, particularly of bovine origin. The market for such pharmaceutical and cosmetic products for human use derived from animals is in excess of $7 billion. The technology is being used in the manufacturing of HemoBioTech's lead product HemoTech, potentially the first viable substitute for human blood. HemoTech is composed of chemically modified bovine hemoglobin.
Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information contact, Dr. Arthur Bollon at: 972-455-8955 or email@example.com or visit our website at: http://www.hemobiotech.com.
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre- clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-K for the year ending December 31, 2007, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.
SOURCE: HemoBioTech, Inc.